p53 and β-Catenin Expression in Gallbladder Carcinoma: Translational Insights for Pediatric Cancer Biology.
The tumor suppressor p53 and the Wnt pathway effector β-catenin represent two of the most frequently dysregulated molecular components across human malignancies. Although gallbladder cancer (GBC) predominantly affects adults, the pattern and clinicopathological correlates of p53 and β-catenin dysregulation in GBC may illuminate how these pathways behave in different biological contexts, including developmental and pediatric oncological settings, where analogous pathway alterations drive distinct tumor types.
To characterize p53 and β-catenin expression patterns in gallbladder carcinoma by immunohistochemistry, correlate findings with clinicopathological parameters, and discuss in a qualified, hypothesis-generating framework the parallels and divergences between these pathway alterations and those reported in pediatric malignancies.
A cross-sectional study analyzed 61 neoplastic and 49 non-neoplastic gallbladder lesions (2017-2021) using standardized immunohistochemistry for p53 (clone DO-7; Dako/Agilent, 1:100) and β-catenin (clone E247; Abcam, 1:200). Expression patterns were correlated with clinicopathological parameters using chi-square and Fisher's exact tests. Findings were discussed in the context of published pediatric cancer literature, with explicit acknowledgment of inter-study methodological heterogeneity.
p53 overexpression (defined as >20% nuclear positivity) occurred in 78.2% of GBC cases versus 11.1% of benign lesions, correlating significantly with tumor grade and stage (p<0.05). Aberrant β-catenin expression (cytoplasmic/nuclear) was observed in 81.8% of malignant cases, with nuclear localization in 36.3%, correlating with poor differentiation. These patterns qualitatively parallel though are not directly quantitatively comparable to those reported in pediatric hepatoblastoma, Wilms' tumor, and pediatric sarcomas.
p53 and β-catenin dysregulation in GBC exhibits qualitative parallels to patterns reported in pediatric cancers, suggesting shared oncogenic pathway biology. These observations are hypothesis-generating and warrant validation through functional studies in appropriate preclinical models before therapeutic implications can be drawn.
To characterize p53 and β-catenin expression patterns in gallbladder carcinoma by immunohistochemistry, correlate findings with clinicopathological parameters, and discuss in a qualified, hypothesis-generating framework the parallels and divergences between these pathway alterations and those reported in pediatric malignancies.
A cross-sectional study analyzed 61 neoplastic and 49 non-neoplastic gallbladder lesions (2017-2021) using standardized immunohistochemistry for p53 (clone DO-7; Dako/Agilent, 1:100) and β-catenin (clone E247; Abcam, 1:200). Expression patterns were correlated with clinicopathological parameters using chi-square and Fisher's exact tests. Findings were discussed in the context of published pediatric cancer literature, with explicit acknowledgment of inter-study methodological heterogeneity.
p53 overexpression (defined as >20% nuclear positivity) occurred in 78.2% of GBC cases versus 11.1% of benign lesions, correlating significantly with tumor grade and stage (p<0.05). Aberrant β-catenin expression (cytoplasmic/nuclear) was observed in 81.8% of malignant cases, with nuclear localization in 36.3%, correlating with poor differentiation. These patterns qualitatively parallel though are not directly quantitatively comparable to those reported in pediatric hepatoblastoma, Wilms' tumor, and pediatric sarcomas.
p53 and β-catenin dysregulation in GBC exhibits qualitative parallels to patterns reported in pediatric cancers, suggesting shared oncogenic pathway biology. These observations are hypothesis-generating and warrant validation through functional studies in appropriate preclinical models before therapeutic implications can be drawn.